louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06382597: Four Weeks of Nordic Hamstring Exercises Impact the Strength and Balance of the Hamstring Muscle Group
Official title: Four Weeks of Nordic Hamstring Exercises Impact the Strength and Balance of the Hamstring Muscle Group
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hamstring Injury
Lead sponsor: Gdansk University of Physical Education and Sport
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 2
Sex: ALL
Minimum age (years): 19
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will involve students of the Academy of Physical Education and Sport in Gdańsk, aged 19-26 who practice amateur football.

Brief summary: The aim of the study is to assess the impact of 4 weeks of eccentric Nordic Hamstring Exercise training on changes in the hamstring muscle group, as well as to analyze parameters such as maximum muscle strength of the knee flexors, RFD (rate of force development) and static balance, dynamics for the dominant leg.

Detailed description: Research procedure: Nordic Hamstring Exercise training covers a period of 4 weeks, during which the volunteer exercises 3 times a week for 3 sets, each set consisting of 3 repetitions of NHE. Before starting eccentric exercises, you will warm up for 15 minutes. After each series, there will be a 2-minute passive break, during which the subject will rest. In the first week, the subject will exercise under the supervision of the instructor, in the next three weeks the subject will exercise at home after prior instruction.

Eligibility criteria: Inclusion Criteria:

* healthy people aged 19-26,
* no injuries,
* athletes, people practicing sports as amateurs

Exclusion Criteria:

* during the period of greatest training load related to the discipline,
* overload changes in the joints: knee, hip and lumbar-sacral,
* pain,
* muscle fatigue, overtraining,
* in strength sports a few weeks before the start,
* inflammation of the osteoarticular and ligamentous elements of the lower limbs,
* previous injuries, surgical procedures within 6 months before the intervention

Primary outcomes:
measure: Biodex Balance System
timeFrame: 15 min
Secondary outcomes:
measure: Biodex System
timeFrame: 20 min
Other outcomes:
Locations:
city: Gdańsk
country: Poland
facility: Academy of Physical Education in Gdańsk
Study officials:
affiliation: Department of Basic Physiotherapy, Gdansk University of Physical Education and Sport, Gdansk, Poland
name: Magdalena Podczarska-Głowacka
role: STUDY_CHAIR
References:
Clinical trial NCT03529097: Evaluation of the Roll of IV Fluids in the Treatment of Renal Colic
Official title: Randomized Controlled Trial to Evaluate the Efficiency of IV Fluids in the Treatment of Renal Colic
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Renal Colic
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2018-05-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomised controlled trial to evaluate the role of IV fluids in renal colic.

Detailed description: A RCT (Randomized Controlled Trial)to evaluate the role of 0.9% NACL (sodium chloride) IV fluids during an acute renal colic. The 2 arms will include -

1. 2 liters of 0.9% NACL IV fluids with pain killers
2. only pain killers The object is to find out if the IV fluids has any advantage in the care of renal colic. Does it helps to relive the pain? Does the stone eject earlier? Will there be fewer interventions?

Eligibility criteria: Inclusion Criteria:

* above 18 years
* clinical renal colic
* a radiological proof (CT,US) to urolithiasis

Exclusion Criteria:

* below 18 years
* has a contraindication for IV fluids (such as CHF (Congestive Heart Failure)etc.)

Primary outcomes:
measure: Stone ejection without intervention
timeFrame: 1 month
measure: The need for urological intervention
timeFrame: 0 to 1 month
measure: Pain
timeFrame: 6 hours
Secondary outcomes:
measure: Pain
timeFrame: 1 Hour
measure: Pain
timeFrame: 1 month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02236897: PET Imaging in ALS Patients
Official title: Metabotropic Glutamate Receptor 5 (mGluR5) Imaging in Amyotrophic Lateral Sclerosis (ALS) Patients and Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: ALS Association
First posted: 2014-09-11
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data, preliminary data in ALS mutant mice, and our recently published data using brain PET scans to image the metabotropic glutamate receptor type 5 (mGluR5) in healthy human volunteers.


Eligibility criteria: Inclusion Criteria:

* Male or female ALS patients, ranging in age from 18-80.
* Must meet El Escorial Criteria for Probable or Definite ALS.
* Disease duration \>1 year, but \<3 years.
* Weakness in at least two extremities.
* Forced vital capacity less than 80% and greater than 50%.

Exclusion Criteria:

* Documented orthopnea or otherwise unable to lie flat in a PET scanner for 90 minutes.
* Presence of pacemakers, aneurysm clips, shrapnel, or other implanted metallic devices that would preclude an MRI scan.
* Absence of sufficient collateral arterial circulation for radial arterial line placement in both wrists.
* Significant abnormalities of hepatic or renal function, or illicit substance use.
* Positive drug screen. (Subjects currently taking prescribed narcotic medication who have a positive drug screen for this medication will not be excluded. Medication history will be obtained during screening).
* Weighs \> 350 lbs.

Primary outcomes:
measure: Glutamate Receptor Distribution
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Lyle Ostrow, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03912597: VR-assisted Curriculum on Depression for Stigma Reduction
Official title: Reducing Stigma Against Depression: Designing and Implementing a VR-assisted Curriculum to Reduce Students' Perceptions of Patients With Depression
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Control
Behavior
Keywords: virtual reality
stigma reduction
depression
mental health campaigns
user experience
enjoyment
presence
Lead sponsor: Yale-NUS College
Sponsor class: OTHER
First posted: 2019-04-11
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Two randomised controlled trials will be conducted to evaluate a virtual reality (VR) simulation designed to reduce stigma against depression. Qualitative interviews will also be carried out to evaluate the VR simulation.

Detailed description: The investigators examine the impact of a VR-assisted curriculum on stigma reduction towards individuals with depression. This is done through the development and evaluation of a VR-assisted curriculum that promotes stigma reduction towards depression among tertiary-aged students. Collection of data will provide insights about the effectiveness of VR's immersive quality in enhancing stigma reduction skills through measures of attitudes, beliefs and knowledge about depression. In the first study, VR is compared with traditional pamphlets in an information sharing booth about depression. In the second study, participants attend a 30-min session where they undergo an educational curriculum with either a VR or standard video as adjunctive tools.

Eligibility criteria: Inclusion Criteria:

* Tertiary students from NUS and Yale-NUS only

Exclusion Criteria:

* History of medical or psychiatric disorder; History of motion sickness, dizziness or epilepsy; (For reliability and safety of heart-rate monitoring) Tattoos near the wrist and/or nickel or acrylate allergies

Primary outcomes:
measure: Stigmatising beliefs towards depression
timeFrame: 2 minutes
measure: Stigmatising attitudes towards depression
timeFrame: 5 minutes
measure: Knowledge about depression
timeFrame: 2 minutes
measure: Video Enjoyment
timeFrame: 1 minute
measure: Video Presence
timeFrame: 1 minute
Secondary outcomes:
measure: Affect (PANAS)
timeFrame: 3 minutes
measure: Heart rate live tracking
timeFrame: 4 minutes
measure: Qualitative feedback about VR video
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Yale-NUS College
Study officials:
References:
Clinical trial NCT06606197: Hepatitis C Prevalence in Men Who Have Sex With Men
Official title: CRIBADO DE VIRUS DE LA HEPATITIS C en Hombres Que Tienen Sexo Con Hombres (HSH) Sitges
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C
Keywords: Hepatitis C
Lead sponsor: Consorci Sanitari de l'Alt Penedès i Garraf
Sponsor class: OTHER
First posted: 2024-09-20
Enrollment: 454
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population attending the \&#34;International Bears Sitges Week\&#34; festival in September 2022 in Sitges, Barcelona.

Brief summary: This is an observational study aimed at determining the prevalence of hepatitis C in a specific population: men who have sex with men.


Eligibility criteria: Inclusion Criteria:

* Having sex with men

Exclusion Criteria:

* Refusal to participate in the trial

Primary outcomes:
measure: Number of participants with Hepatitis C screening positive
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Vilafranca del Penedès
country: Spain
facility: Consorci Sanitari Alt Penedès Garraf
state: Barcelona
Study officials:
affiliation: CSAPG
name: Sonia Albertos, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Albertos S, Majo FX, Esteban R, Colom J, Buti M. A large-scale screening of hepatitis C among men who have sex with men in the community using saliva point-of-care testing. Front Public Health. 2024 Dec 9;12:1478195. doi: 10.3389/fpubh.2024.1478195. eCollection 2024.
Clinical trial NCT00480805: HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)
Official title: HYZAAR Versus Ramipril Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Hypertension
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2007-05-31
Enrollment: 312
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A study to test the safety and efficacy of HYZAAR as compared to Ramipril in patients with type 2 diabetes mellitus (high blood sugar) and hypertension (high blood pressure).


Eligibility criteria: Inclusion Criteria:

* Patient is at least 18 years old, has been diagnosed with type 2 diabetes mellitus

Exclusion Criteria:

* Patient has renal disease, malignant hypertension, uncontrolled type 2 diabetes mellitus, history of stroke, TIA (Transient Ischemic Attacks) , or heart disease

Primary outcomes:
measure: To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4
Secondary outcomes:
measure: To determine the safety anf tolerability of HYZAAR as compared to Ramipril as seen in overall adverse experiences for the duration of the study
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Fox JC, Leight K, Sutradhar SC, Demopoulos LA, Gleim GW, Lewin AJ, Bakris GL. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug;6(8):437-42; quiz 443-4. doi: 10.1111/j.1524-6175.2004.03488.x.
Clinical trial NCT01619605: The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis
Official title: The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food (Shrimp) Allergy
Keywords: tryptases
anaphylaxis
shrimp allergy
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2012-06-14
Enrollment: 39
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study was to investigate the utility of serum tryptase for the confirmation of shrimp-induced anaphylaxis.

Detailed description: The diagnosis of anaphylaxis is based primarily on the clinical history. In some circumstances, inability to confirm the clinical diagnosis such as present with unusual manifestation, or when skin signs are absent likely contributes to underrecognition and undertreatment of the disease.

Currently, products of mast cell activation (histamine and total tryptase) can be measure in clinical laboratories as markers of acute anaphylaxis events, however these tests have clinically relevant limitations.

Therefore, development of laboratory tests with improved sensitivity and specificity that will support the clinical diagnosis of anaphylaxis are needed.

In addition, shrimp is the major cause of seafood anaphylaxis among Thai children.

Eligibility criteria: Inclusion Criteria:

* a history of shrimp allergy

Exclusion Criteria:

* severe anaphylactic reaction from seafood
* pregnancy
* underlying diseases such as cardiovascular, hepatobiliary, and renal diseases
* on systemic corticosteroid or β-blocking agents

Primary outcomes:
measure: Change of Serum tryptases
timeFrame: baseline and 60 minutes after the onset of symptoms
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkoknoi
country: Thailand
facility: Pediatric allergy clinic, Faculty of Medicine Siriraj Hospital, Mahidol University
state: Bangkok
Study officials:
affiliation: Mahidol University
name: Orathai Piboonpocanun, Assoc.Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04218305: Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus
Official title: Study of Using Serum Fetuin-A as a Marker in Obesity and Type 2 Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabete Type 2
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2020-01-06
Enrollment: 400
Sex: ALL
Minimum age (years): 45
Maximum age (years): 60
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Brief summary: The aim of this study is to assess the significance of serum fetuin-A as a marker of obesity and type 2 diabetes mellitus. We used multiple statistical approaches to determine that the fetuin-A level is correlated to body mass index (BMI) as well as random blood sugar in type 2 diabetic patients. Also, we found that there is a Positive correlation between the serum fetuin-A levels and the level of glycosylated hemoglobin (HbA1c) in diabetic patients.

Detailed description: The study was a case-control study. We started the study to be performed on eighty subjects divided into four groups:

The first group: include twenty subjects with type 2 diabetes mellitus The second group: include twenty obese subjects whose body mass index is 30 or over The third group: include twenty obese subjects with type 2 diabetes mellitus The fourth group includes twenty apparently healthy subjects as control.

In this study, we concluded that:

1. Serum fetuin-A can be used as a biomarker and independent risk factor and marker for diagnosis of DM and DM has a detrimental effect on serum fetuin-A fetuin-A could be of relevance for the development of insulin resistance
2. Higher fetuin-A concentrations were associated with type 2 diabetes and insulin resistance
3. Increased serum fetuin-A levels constitute an independent marker of lipid profile.
4. fetuin-A may play a role in the pathogenesis of T2DM.
5. The inhibition of insulin receptor by fetuin-A may lead to increased lipolysis and efflux of free fatty acids from adipose tissue. This could explain associated dyslipidemia observed in type 2 diabetic patients in the present study.

Finally, our finding that high plasma fetuin-A levels predict the incidence of type 2 diabetes independently of other established risk factors supports the hypothesis that fetuin-A may play a role in the development of type 2 diabetes.

Eligibility criteria: Inclusion Criteria:

* • The study included obese and type 2 diabetic patients aged 45-60 years old. and control healthy adult persons

Exclusion Criteria:

* • Cardiac disease and Hypertensive disease

  * Respiratory disease
  * Renal disease
  * GIT and Liver disease
  * Rheumatologic disease
  * Blood disease
  * Endocrine disease except for type 2 diabetes mellitus
  * All with a specific therapeutic drug history.

Primary outcomes:
measure: 1- Study of human serum fetuin-A and whether it is involved in insulin resistance
timeFrame: Baesline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06384105: Study of the Patient Radiation Dose During Five Endourological Procedures
Official title: Prospective Multicentric Study of the Patient Radiation Dose During Five Endourological Procedures: Insertion and Replacement of Ureteral Stent, URS, (Mini-)PCNL/ PCNL and ESWL/SWL
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Radiation Exposure
Urolithiasis
Lead sponsor: Universiteit Antwerpen
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 870
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In the medical world more and more procedures are performed with the use of ionizing radiation (x-ray), both diagnostic and therapeutic. The main and most known risk is the development of malignancies as a result of the use of ionizing radiation.

Purpose of this study: To examine the patient radiation dose (PRD) if the frames per second (FPS) are set differently during the five most performed endourological procedures where fluoroscopy is used (insertion/replacement of ureteral stent, (mini-)percutaneous nephrolithotomy (PCNL/PNL), ureterorenoscopy (URS) and extracorporeal shock wave lithotripsy (ESWL/SWL)) and to propose an acceptable PRD for these procedures in a multicentric study.


Eligibility criteria: Inclusion Criteria:

* all patients who receive insertion/replacement of ureteral stent, URS (flexible or semirigid), (mini-)PCNL (including ECIRS) or ESWL under fluoroscopic with or without ultrasonic guidance
* Only cases performed or directly supervised by experts

Exclusion Criteria:

* Bilateral cases
* Diagnostic ureterorenoscopies
* Antegrade ureteroscopies
* Procedures for Upper Tract Urothelial Carcinoma (UTUC)
* Procedures on children (aged \<18 years)
* Pregnant women
* Abnormal urinary anatomy (e.g. ureteral duplication, pelvic kidney, bladder derivation, horseshoe kidney)

Primary outcomes:
measure: Dose limit
timeFrame: 1 year
Secondary outcomes:
measure: Difference in PRD
timeFrame: 1 year
measure: PRD different centres
timeFrame: 1 year
measure: PRD difference complicated cases
timeFrame: 1 year
Other outcomes:
Locations:
city: Brasschaat
country: Belgium
facility: AZ Klina
state: Antwerp
city: Edegem
country: Belgium
facility: UZA
state: Antwerp
Study officials:
affiliation: Universiteit Antwerpen
name: Vincent De Coninck, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05862805: PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis
Official title: The Role of Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), Tissue Factor Pathway Inhibitor (TFPI), and Endometrial Endothelial Cells in Uterine Hemostasis in Humans
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Menstrual Bleeding, Heavy
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2023-05-17
Enrollment: 70
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.

Detailed description: The purpose of this study is to learn if human endometrial endothelial cells (HEECs) regulate human uterine hemostasis through the up and down-regulation of pro- and anti-coagulant factors in menstrual blood including PAI-1, factor XI (FXI)-PAI-1 complex, tPA, and TFPI.

This study will enroll participants with heavy menstrual bleeding (HMB) and participants without HMB. Coagulation factors will be measured in menstrual blood and mRNA for these factors will be quantified from cultured HEECS from endometrial biopsies and compared between groups.

Eligibility criteria: Inclusion Criteria:

* Regularly menstruating participants between 18-45 years of age

Exclusion Criteria:

* Pregnancy within 3 months of enrollment
* Lactating at the time of enrollment
* Hormonal contraceptive use or use of the copper intrauterine device (IUD)
* Antifibrinolytic use
* Inherited or acquired bleeding disorder or anticoagulant use
* Known structural cause of HMB
* Inability to complete PBACs
* Unwilling to refrain from sexual intercourse for the two weeks prior to endometrial biopsy

Primary outcomes:
measure: Total number of mRNA copies from HEEC culture of tPA
timeFrame: Enrollment to 60 days
measure: Total number of mRNA copies from HEEC culture of PAI-1
timeFrame: Enrollment to 60 days
measure: Total number of mRNA copies from HEEC culture of TFPI
timeFrame: Enrollment to 60 days
measure: Change in the numerical score of Pictorial Blood Loss Assessment
timeFrame: Enrollment to 60 days
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: OHSU
state: Oregon
Study officials:
References: